Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. The use of the electromotive drug administration system in patients with superficial bladder cancer: a review of the clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions There is little evidence on the efficacy and safety of EDMA to treat non-muscle invasive bladder cancer. However the one article included was considered high quality and suggested administrating mitomycin via EDMA prior to transurethral tumour resection (TURBT) results in improved long term outcomes compared to TURBT alone, or passive diffusion of mitomycin post-TURBT. No evidence on the cost effectiveness of EDMA for bladder cancer was identified Indexing Status Subject indexing assigned by CRD MeSH Drug Delivery Systemss; Urinary Bladder Neoplasms Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000153 Date abstract record published 06/03/2015 |